Royal Bank of Canada’s Bio-Rad Laboratories Class A BIO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$4.79M Buy
17,198
+2,487
+17% +$716K ﹤0.01% 2445
2025
Q4
$4.46M Sell
14,711
-161,380
-92% -$50.4M ﹤0.01% 2512
2025
Q3
$49.4M Buy
176,091
+24,533
+16% +$6.68M 0.01% 1026
2025
Q2
$36.6M Buy
151,558
+121,248
+400% +$28.7M 0.01% 1120
2025
Q1
$7.38M Buy
30,310
+6,100
+25% +$1.84M ﹤0.01% 1966
2024
Q4
$7.95M Buy
24,210
+725
+3% +$246K ﹤0.01% 1966
2024
Q3
$7.86M Sell
23,485
-3,894
-14% -$1.24M ﹤0.01% 1946
2024
Q2
$7.48M Sell
27,379
-4,378
-14% -$1.27M ﹤0.01% 1873
2024
Q1
$11M Sell
31,757
-851
-3% -$280K ﹤0.01% 1621
2023
Q4
$10.5M Sell
32,608
-47,649
-59% -$14.9M ﹤0.01% 1691
2023
Q3
$28.8M Buy
80,257
+1,660
+2% +$640K 0.01% 964
2023
Q2
$29.8M Sell
78,597
-6,919
-8% -$2.82M 0.01% 958
2023
Q1
$41M Buy
85,516
+8,228
+11% +$3.85M 0.01% 764
2022
Q4
$32.5M Buy
77,288
+10,890
+16% +$4.4M 0.01% 872
2022
Q3
$27.7M Buy
66,398
+9,543
+17% +$4.76M 0.01% 885
2022
Q2
$28.1M Buy
56,855
+343
+0.6% +$179K 0.01% 912
2022
Q1
$31.8M Buy
56,512
+6,819
+14% +$4.11M 0.01% 962
2021
Q4
$37.5M Sell
49,693
-2,787
-5% -$2.09M 0.01% 995
2021
Q3
$39.1M Sell
52,480
-4,175
-7% -$3.13M 0.01% 884
2021
Q2
$36.5M Buy
56,655
+5,650
+11% +$3.44M 0.01% 925
2021
Q1
$29.1M Buy
51,005
+983
+2% +$582K 0.01% 1032
2020
Q4
$29.2M Buy
50,022
+8,290
+20% +$4.72M 0.01% 998
2020
Q3
$21.5M Buy
41,732
+7,072
+20% +$3.58M 0.01% 1031
2020
Q2
$15.6M Buy
34,660
+6,397
+23% +$2.82M 0.01% 1184
2020
Q1
$9.91M Buy
28,263
+2,254
+9% +$829K ﹤0.01% 1343
2019
Q4
$9.63M Buy
26,009
+17,745
+215% +$6.26M ﹤0.01% 1661
2019
Q3
$2.75M Buy
8,264
+1,587
+24% +$518K ﹤0.01% 2505
2019
Q2
$2.09M Buy
6,677
+798
+14% +$239K ﹤0.01% 2734
2019
Q1
$1.8M Buy
5,879
+1,415
+32% +$382K ﹤0.01% 2776
2018
Q4
$1.03M Sell
4,464
-7,552
-63% -$2.03M ﹤0.01% 3137
2018
Q3
$3.76M Buy
12,016
+10,498
+692% +$3.26M ﹤0.01% 2342
2018
Q2
$438K Buy
1,518
+735
+94% +$203K ﹤0.01% 3878
2018
Q1
$196K Sell
783
-292
-27% -$74.3K ﹤0.01% 4331
2017
Q4
$257K Sell
1,075
-5,191
-83% -$1.26M ﹤0.01% 4268
2017
Q3
$1.39M Buy
6,266
+2,942
+89% +$662K ﹤0.01% 2948
2017
Q2
$752K Sell
3,324
-21,936
-87% -$4.78M ﹤0.01% 3326
2017
Q1
$5.04M Buy
25,260
+23,559
+1,385% +$4.54M ﹤0.01% 1910
2016
Q4
$312K Buy
1,701
+550
+48% +$93.8K ﹤0.01% 4164
2016
Q3
$189K Sell
1,151
-5,275
-82% -$801K ﹤0.01% 4470
2016
Q2
$919K Sell
6,426
-1,559
-20% -$222K ﹤0.01% 3187
2016
Q1
$1.09M Buy
7,985
+6,414
+408% +$842K ﹤0.01% 2980
2015
Q4
$218K Buy
1,571
+1,018
+184% +$141K ﹤0.01% 4457
2015
Q3
$74K Buy
553
+286
+107% +$41.2K ﹤0.01% 4934
2015
Q2
$41K Hold
267
﹤0.01% 5327
2015
Q1
$36K Sell
267
-12
-4% -$1.49K ﹤0.01% 5112
2014
Q4
$34K Sell
279
-3,463
-93% -$399K ﹤0.01% 5197
2014
Q3
$424K Sell
3,742
-4,460
-54% -$528K ﹤0.01% 3625
2014
Q2
$982K Buy
8,202
+6,369
+347% +$778K ﹤0.01% 2856
2014
Q1
$234K Sell
1,833
-2,161
-54% -$277K ﹤0.01% 3977
2013
Q4
$495K Sell
3,994
-7,537
-65% -$918K ﹤0.01% 3428
2013
Q3
$1.36M Buy
11,531
+8,814
+324% +$1.04M ﹤0.01% 2496
2013
Q2
$305K Buy
+2,717
New +$319K ﹤0.01% 3563

Other funds holding BIO

Royal Bank of Canada's BIO Position: Q1 2026 in Review

Royal Bank of Canada increased its Bio-Rad Laboratories Class A (BIO) stake by 17% in Q1 2026, buying an estimated $716K and bringing the position to 17,198 shares worth $4.79M. The position accounts for ﹤0.01% of the portfolio, ranked #2445.

Royal Bank of Canada first reported a position in BIO in Q2 2013 and has held it in 52 quarters since. The position peaked at $49.4M in Q3 2025. 392 funds tracked by Wall St. Rank hold BIO as of Q1 2026.

  • Royal Bank of Canada held 17,198 shares of Bio-Rad Laboratories Class A worth $4.79M as of Q1 2026.
  • Royal Bank of Canada bought 2,487 Bio-Rad Laboratories Class A shares in Q1 2026, an estimated $716K.
  • Bio-Rad Laboratories Class A made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #2445 holding.
  • Royal Bank of Canada first reported a position in Bio-Rad Laboratories Class A in Q2 2013 and has held it in 52 quarters since.
  • Royal Bank of Canada's Bio-Rad Laboratories Class A position peaked at $49.4M in Q3 2025.
  • 392 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.